TAPIMMUNE Inc. and the Vaccine & Gene Therapy Institute of Florida formed a partnership to advance TapImmune’s cancer vaccines into phase II clinical trials for the treatment of breast and ovarian cancers.
These cancer vaccine candidates were developed by the institute’s director of cancer vaccines and immune therapies program, Keith Knutson. VGTI Florida will work with TapImmune to design and execute the clinical programs, including the design of the clinical protocols, and selection of clinical trial sites and external manufacturing and clinical resources.
TapImmune had previously announced the licensing of these vaccines technologies for the treatment of HER2/neu breast cancer and ovarian and breast cancer developed in the laboratory of Knutson while he was at the Mayo Clinic.
